# A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

> **NCT04486352** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 148 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Atezolizumab - 28 Day Cycle
- **DRUG:** Bevacizumab
- **DRUG:** Ipatasertib
- **DRUG:** Talazoparib
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab - 21 Day Cycle
- **DRUG:** Inavolisib
- **DRUG:** Letrozole
- **DRUG:** Giredestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04486352
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-10
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486352, "A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04486352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*